NCT05201690View on ClinicalTrials.gov

Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV116 in Healthy Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

36

Participants

Timeline

Start Date

December 14, 2021

Primary Completion Date

January 19, 2022

Study Completion Date

January 23, 2022

Conditions
Healthy Subjects
Interventions
DRUG

VV116 200 mg Group

Drug: VV116 9 subjects will receive VV116 200 mg, orally, QD12h, 5.5 days ;

DRUG

VV116 400mg Group

Drug: VV116 9 subjects will receive VV116 400 mg, orally, QD12h, 5.5 days ;

DRUG

VV116 600mg Group

Drug: VV116 9 subjects will receive VV116 600 mg, orally, QD12h, 5.5 days ;

Trial Locations (1)

Unknown

Shanghai Xuhui Central Hospital, Shanghai

All Listed Sponsors
lead

Vigonvita Life Sciences

INDUSTRY

NCT05201690 - Safety and Pharmacokinetics Study of Multiple Ascending Doses of VV116 in Healthy Volunteers | Biotech Hunter | Biotech Hunter